Merck KGaA says the agreed bid for SpringWorks is final
April 28 (Reuters) - Merck KGaA's CEO said on Monday that the German group's takeover price for U.S. biotech firm SpringWorks SWTX.O was firmly agreed and "final", when asked about the potential of any rival bidders for the takeover target. (Reporting by Ludwig Burger, editing by Rachel More) ((ludwig.burger@thomsonreuters.com;))
Recent news on SpringWorks Therapeutics
See all newsBrief: Merck KGaA Completes Acquisition Of Springworks Therapeutics
Brief: Springworks Therapeutics Expects Nirogacestat Decision From European Commission In Q3
Brief: EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN